Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Tilray Brands
TLRY
Tilray Brands
Fragmented Legalization And Oversupply Will Hamper International Scaling
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$0.60
91.7% overvalued
intrinsic discount
22 Aug
US$1.15
Loading
1Y
-40.4%
7D
11.7%
Author's Valuation
US$0.6
91.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$0.6
91.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-2b
926m
2014
2017
2020
2023
2025
2026
2028
Revenue US$925.8m
Earnings US$215.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.46%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.45%
Calculation
US$214.96m
Earnings '28
x
4.53x
PE Ratio '28
=
US$973.39m
Market Cap '28
US$973.39m
Market Cap '28
/
1.35b
No. shares '28
=
US$0.72
Share Price '28
US$0.72
Share Price '28
Discounted to 2025 @ 6.45% p.a.
=
US$0.60
Fair Value '25
